Nine-year trends in clinically relevant reduced susceptibility of HIV-1 to antiretrovirals

Journal of Clinical Virology

Volumn 44, Issue 3, 2009, Pages 190-194

  Sista, P ^a   Rinehart, A ^b   Wasikowski, B ^c   Winters, B ^d   Pattery, T ^d   Bacheler, L ^a  

^a VircoLab Inc   (United States)

^b Tibotec Therapeutics   (United States)

^c xLeo Inc   (United States)

^d Virco BVBA   (Belgium)

Author keywords

Calculated fold change; Clinical cut offs; HIV 1 resistance trends; Mutation prevalence; Phenotypic susceptibility

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; VIRUS GENE; VIRUS MUTATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; MUTATION, MISSENSE;

EID: 60449087073     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2008.12.005     Document Type: Article

References (22)

1. Clavel F., and Hance A.J. HIV drug resistance. N Engl J Med 350 (2004) 1023-1035
2. Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther 9 (2004) 695-702
3. Richman D.D., Morton S.C., Wrin T.F., Hellman N., Berry S., Shapiro S.F., et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 18 (2004) 1393-1401
4. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., et al. Antiretroviral drug-resistance among patients recently infected with HIV. N Engl J Med 347 (2002) 385-394
5. Geretti A.M. Epidemiology of antiretroviral drug resistance in drug-naïve persons. Curr Opin Infect Dis 20 (2007) 22-32
6. Wensing A.M.J., Vercauteren J., van de Vijver D.A., Albert J., Asjo B., Balotta C., et al. SPREAD programme: transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 22 (2008) 625-635
7. McColl D.J., Chappey C., Parkin N.T., and Miller M.D. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database. Antivir Ther 13 (2008) 189-197
8. Van Laethem K., and Vandamme A.M. Interpreting resistance data for HIV-1 therapy management-know the limitations. AIDS Rev 8 (2006) 37-43
9. Hertogs K., de Béthune M.-P., Miller V., Ivens T., Schel P., Van Cauwenberge A., et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 42 (1998) 269-276
10. Petropoulos C.J., Parkin N.T., Limoli K.L., Lie Y.S., Wrin T., Huang W., et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44 (2000) 920-928
11. Vermeiren H., Van Craenenbroeck E., Alen P., Bacheler L., Picchio G., Lecocq P., et al. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods 145 (2007) 47-55
12. Winters B.W., Montaner J., Harrigan P.R., Gazzard B., Pozniak A., Miller M.D., et al. Determination of clinically relevant cut-offs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data. J Acquir Immune Defic Syndr 48 (2007) 26-34
13. Shafer R.W., Rhee S.Y., Pillay D., Miller V., Sandstrom P., Schapiro J.M., et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 21 (2007) 215-223
14. Los Alamos National Laboratory Database, Los Alamos, NM, USA. www.hiv.lanl.gov.
15. The French ANRS (National Agency for AIDS Research): HIV French Resistance http://www.hivfrenchresistance.org/2008/tab1.html.
16. Stanford University HIV Drug Resistance Database. http://hivdb.stanford.edu/index.html.
17. US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents January 2008. AIDS info web site: http://AIDSinfo.nih.gov.
18. Guidelines for the clinical management and treatment of HIV-infected adults in Europe/Version 2, December 2007 at the EACS web site: http://www.eacs.eu/guide/index.htm.
19. Molina J.-M. Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs 68 (2008) 567-578
20. Mo H., King M.S., King K., Molla A., Brun S., and Kempf D. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol 79 (2005) 3329-3338
21. Ait-Khaled M., Rakik A., Griffin P., Stone C., Richards N., Thomas D., Falloon J., and Tisdale M. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. Antivir Ther 8 (2003) 111-120
22. Colonno R., Rose R., Mclaren C., Thiry A., Parkin N., and Friborg J. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naïve HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 189 (2004) 1802-1810